Stockscreener 앱 받기
0.68
1.45%
-0.010
시간 외 거래:
.68
전일 마감가:
$0.69
열려 있는:
$0.72
하루 거래량:
1.02M
Relative Volume:
1.96
시가총액:
$28.54M
수익:
$3.26M
순이익/손실:
$-19.52M
주가수익비율:
-1.70
EPS:
-0.4
순현금흐름:
$-24.10M
1주 성능:
+16.08%
1개월 성능:
-12.82%
6개월 성능:
-11.78%
1년 성능:
-42.86%
1일 변동 폭
$0.6126
$0.73
1주일 범위
$0.565
$0.73
52주 변동 폭
$0.565
$1.49
Scynexis Inc Stock (SCYX) Company Profile
명칭
Scynexis Inc
전화
201-884-5485
주소
1 EVERTRUST PLAZA, JERSEY CITY, NJ
SCYX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SCYX
Scynexis Inc
|
0.68 | 28.96M | 3.26M | -19.52M | -24.10M | -0.40 |
|
ZTS
Zoetis Inc
|
122.06 | 51.07B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.30 | 44.42B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.87 | 42.75B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
24.21 | 27.86B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
474.82 | 20.44B | 3.08B | 1.24B | 1.07B | 25.61 |
Scynexis Inc Stock (SCYX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-01-22 | 개시 | Guggenheim | Buy |
| 2021-01-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-07-11 | 업그레이드 | Needham | Hold → Buy |
| 2018-06-27 | 개시 | Maxim Group | Buy |
| 2017-10-24 | 개시 | Guggenheim | Buy |
| 2017-07-10 | 개시 | ROTH Capital | Buy |
| 2017-05-09 | 다운그레이드 | Needham | Buy → Hold |
| 2017-03-03 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-10-20 | 개시 | H.C. Wainwright | Buy |
| 2016-10-07 | 업그레이드 | WBB Securities | Buy → Strong Buy |
| 2016-10-03 | 재개 | Brean Capital | Buy |
| 2016-08-17 | 개시 | Guggenheim | Buy |
| 2016-08-09 | 재확인 | Needham | Buy |
| 2016-08-09 | 업그레이드 | WBB Securities | Speculative Buy → Buy |
| 2016-03-28 | 개시 | Brean Capital | Buy |
| 2015-12-29 | 개시 | WBB Securities | Speculative Buy |
| 2015-11-16 | 재확인 | RBC Capital Mkts | Outperform |
| 2015-06-10 | 개시 | Needham | Buy |
| 2014-05-29 | 개시 | Canaccord Genuity | Buy |
| 2014-05-29 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Scynexis Inc 주식(SCYX)의 최신 뉴스
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Will SCYNEXIS Inc. (135A) stock outperform foreign stocksJuly 2025 Action & Risk Managed Trade Strategies - newser.com
Is SCYNEXIS Inc. (135A) stock considered safe havenGap Up & Smart Allocation Stock Tips - newser.com
Analyzing recovery setups for SCYNEXIS Inc. investorsFed Meeting & Fast Gain Stock Trading Tips - newser.com
Will SCYNEXIS Inc. stock recover faster than peersJuly 2025 Update & Technical Pattern Alert System - newser.com
Scynexis Transfers Brexafemme New Drug Application to GSK - MarketScreener
SCYNEXIS, Inc. Completes Transfer of Brexafungerp New Drug Application to Gsk - MarketScreener
Scynexis completes transfer of Brexafemme new drug application to GSK - MarketScreener
SCYNEXIS Completes BREXAFEMME NDA Transfer to GSK, Positioning for Future Milestones and Royalties - Quiver Quantitative
SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK - The Manila Times
Scynexis completes transfer of Brexafemme New Drug Application To GSK - TradingView
SCYNEXIS (NASDAQ: SCYX) transfers BREXAFEMME NDA to GSK, up to $145.5M - Stock Titan
Why SCYNEXIS Inc. (135A) stock stays resilientEarnings Recap Report & Low Risk High Win Rate Stock Picks - newser.com
Is SCYNEXIS Inc. stock attractive for passive investorsMarket Sentiment Report & Long-Term Safe Investment Plans - newser.com
How to build a dashboard for SCYNEXIS Inc. stockEarnings Overview Report & Risk Controlled Daily Trade Plans - newser.com
Scynexis fungerps among funding recipients - BioWorld MedTech
SCYNEXIS receives $7 million annual grant for antifungal research By Investing.com - Investing.com Nigeria
SCYX Secures Federal Grant for Antifungal Research - GuruFocus
Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections - The Manila Times
SCYNEXIS Receives $35 Million NIH Grant to Develop Next-Generation Antifungal Therapies - Quiver Quantitative
Scynexis (NASDAQ: SCYX) fungerps program included in $7M NIH CETR grant - Stock Titan
Why SCYNEXIS Inc. (135A) stock benefits from AI revolutionForecast Cut & AI Forecast Swing Trade Picks - newser.com
Live market analysis of SCYNEXIS Inc.July 2025 Recap & Community Verified Trade Signals - newser.com
Will SCYNEXIS Inc. (135A) stock deliver stable dividendsJuly 2025 Closing Moves & Weekly Top Gainers Alerts - newser.com
How geopolitical tensions affect SCYNEXIS Inc. stockEarnings Recap Summary & Consistent Return Investment Signals - newser.com
SCYX | SCYNEXIS Inc. SEC Filings - MarketWatch
How SCYNEXIS Inc. (135A) stock compares with tech leadersPortfolio Gains Report & Weekly High Return Stock Forecasts - Fundação Cultural do Pará
Is SCYNEXIS Inc. stock attractive for ETFsPortfolio Performance Report & Free Technical Confirmation Trade Alerts - Fundação Cultural do Pará
Is SCYNEXIS Inc. stock ready for a breakoutEarnings Summary Report & Capital Efficient Trading Techniques - newser.com
Can SCYNEXIS Inc. stock maintain growth trajectoryLong Setup & Risk Adjusted Swing Trade Ideas - newser.com
Scynexis Inc (SCYX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.24%
자본화:
|
볼륨(24시간):